Riley Laura E, Cahill Alison G, Beigi Richard, Savich Renate, Saade George
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.
Am J Perinatol. 2017 Jul;34(8):826-832. doi: 10.1055/s-0037-1598070. Epub 2017 Jan 31.
In February 2015, given high rates of use of medications by pregnant women and the relative lack of data on safety and efficacy of many drugs utilized in pregnancy, the National Institute of Child Health and Human Development (NICHD), the Society for Maternal-Fetal Medicine (SMFM), the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) convened a group of experts to review the "current" state of the clinical care and science regarding medication use during the perinatal period. The expert panel chose select medications to demonstrate what existing safety and efficacy data may be available for clinicians and patients when making decisions about use in pregnancy or lactation. Furthermore, these example medications also provided opportunities to highlight where data are lacking, thus forming a list of research gaps. Last, after reviewing the existing vaccine safety surveillance system as well as the legislative history surrounding the use of drugs for pediatric diseases, the expert panel made specific recommendations concerning policy efforts to stimulate more research and regulatory attention on drugs for pregnant and lactating women.
2015年2月,鉴于孕妇用药率较高,且许多孕期使用药物的安全性和有效性数据相对匮乏,美国国立儿童健康与人类发展研究所(NICHD)、母胎医学协会(SMFM)、美国妇产科医师学会(ACOG)和美国儿科学会(AAP)召集了一组专家,以审查围产期用药临床护理和科学的“当前”状况。专家小组选择了特定药物,以展示临床医生和患者在决定孕期或哺乳期用药时可能获得的现有安全性和有效性数据。此外,这些示例药物还提供了突出数据缺失之处的机会,从而形成了一份研究空白清单。最后,在审查了现有的疫苗安全监测系统以及围绕儿科疾病用药的立法历史后,专家小组就推动对孕妇和哺乳期妇女用药进行更多研究及监管关注的政策努力提出了具体建议。